Page 260

Antigens, 59, 64, 66, 120

Anxiety, 4, 10, 36, 84, 90, 109, 127, 142, 153, 165, 168, 203

see also Dysphoria; Euphoria; Sedation

Appetite, viii, 3, 4, 10, 21, 23, 142, 144, 156-159 (passim), 173, 205, 209, 245, 248

set also Nausea; Vomiting; Wasting syndrome

Arachidonic acid, 46, 47, 57

Arachidonyl glycerol (2-AG), 43, 45, 46, 47, 64, 65

Arizona, vii, 1, 17, 18, 104 (footnote)

Arthritis, 28-29

Attitudes

patients, 27-29, 153, 205-206

physicians, prescribing marijuana, 152, 202

risk perception, 104

B

Barbiturates, 143, 172

Basal ganglia, 48-52, 164-166, 168

B cells, 62, 64, 65, 66, 112

see also Lymphocytes, general

Benzodiazepines, 3, 70, 161, 164, 168

Blood pressure

hypertension, 48, 84, 86, 90, 121, 158, 175

hypotension, 121, 150, 151, 175

Brain, general, 3, 35, 36-37, 48-49, 69, 70, 92, 170

basal ganglia, 48-52, 164-166, 168

cannabinoid receptors, 37-65, 69-70

cerebellum, 46, 49, 50, 51, 53, 121, 122

endogenous cannabinoid system, 43-51, 70

globus pallidus, 49, 52, 53, 167

hippocampus, 45-46, 49, 53

putamen, 49, 52, 53, 166

striatum, 46, 51, 53

substantia nigra, 49, 51, 52, 53, 167, 168

thalamus, 46, 49, 51, 52, 53, 55, 165, 167, 169

see Neurons, general

British Medical Association, 180, 244-255 (passim)

Bronchi, 113-114, 115, 119

Buyers' clubs, see Cannibis buyers' clubs

C

Cachexia, 145, 154, 155, 158

see also AIDS wasting; Appetite; Wasting syndrome

Caffeine, 88

California, vii, 1, 16, 17, 18, 101-102, 104, 204, 207

Canada, 150

Cancer

smoking of marijuana as cause, 5, 114, 115, 117-121, 237

treatment of, 22, 23, 142, 145, 154, 158, 159, 204-205;

see also Chemotherapy

Cannabidiol (CBD), 3, 36-37, 47, 60-61, 66, 122, 166, 171-172, 214

Cannabinoids, general, vii, viii-ix, 2-4

defined, 2, 25-26, 194

defined substances, 4

standards, general, 19, 213, 216, 217

see also THC

Cannabinol, 25, 37, 64, 66, 110

see also THC

Cannibis buyers' clubs, viii, 16, 20, 21, 22, 207 defined, 20

Cardiovascular system, 121-122, 251

see also Blood pressure

Case studies, 15, 27-29, 117, 119-120, 254

individual patient accounts, 27-29

single-patient clinical trials, 139, 162

CBD, see Cannabidiol

Cellular biology, 5, 25, 35-59, 69-70, 118-119, 120-121

see also Genetics; Immune system; Receptors; Signal transduction

Cerebellum, 46, 49, 50, 51, 53, 121, 122

Cesamet, see Nabilone

Chemotherapy, viii, 4, 16, 23, 144, 146-153 (passim), 177, 205, 207, 234, 245, 247, 248

Children, 96, 97, 101, 124-125, 139, 149, 167, 210

see also Adolescents

Chronic obstructive pulmonary disease, 114-115

Clinical studies, 15, 30, 34-35, 137, 206, 233-234

glaucoma, 177, 251

movement disorders, 166, 169-170

smoking of marijuana, 9-10

Clinical trials, 7-8, 9-10, 34, 137, 141, 142-143, 203, 209, 211, 218

age factors, 139, 142

AIDS wasting, 8, 156, 213, 245

animal studies vs, 36

epilepsy, 170-172, 173

Investigational New Drugs, 195, 196



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement